You are leaving Medscape Education
Cancel Continue
View All
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
Latest In Oncology
All U.S. Non-U.S.

Select all that apply





          0 global 1 0.5 9 0.5 0.5 Roundtable 0 1
          Can you recognize light-chain amyloidosis in a patient? Start activity
          Light-Chain Amyloidosis: Navigating Heterogeneous Patient Presentation, Swift Diagnosis, and Treatment Planning
          View Details
          Breast Cancer 840 global 1 0.5 9 0.5 0.5 Roundtable 0 1
          Do you consult with the multidisciplinary team (MDT) when making treatment decisions for patients with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC)? Start activity
          Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Shedding Light on the Role of Surgeon, Radiologist, and Oncologist
          View Details
          Atrial Fibrillation 390 global 1 0.5 9 0.5 2 0.5 3 0.5 0.5 Roundtable 0 1
          Why target factor XI/XIa? Experts discuss the rationale, mechanism, and the latest phase 2 data. Start activity
          Addressing Suboptimal Anticoagulation in Atrial Fibrillation: Uncoupling the Potential of Factor XI/XIa Inhibition for Stroke Prevention
          View Details
          Breast Cancer 840 global 1 0.5 9 0.5 2 0.5 3 0.5 0.5 Roundtable 0 1
          What strategies are you using to individualize treatment of HR+/HER2- early breast cancer? Start activity
          Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate
          View Details
          Melanoma 65 global 1 1.0 9 1.0 1.0 Clinical Review 0 1
          Are you familiar with how to incorporate lymphocyte-activation gene 3 (LAG-3) inhibition into the management of metastatic melanoma? Find out more here! Start activity
          LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team
          View Details
          Acute Leukemia 5005273 global 1 1.0 9 1.0 1.0 Journal Article 0 1
          In older patients with AML, fractionated gemtuzumab increased response depth but not toxicity and improved survival in allografted patients. Start activity
          Fractionated vs Single-Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older Patients with AML: the UK NCRI AML18 Trial
          View Details
          Curated Collections
          Curated activities and resources from our partners and committee
          You Might Like
          Because you completed the activity:
          Upcoming Events